Company Description and Summary of Significant Accounting Policies, Liquidity (Details) - USD ($) $ in Thousands |
1 Months Ended | ||
|---|---|---|---|
Nov. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Liquidity [Abstract] | |||
| Cash and cash equivalents | $ 42,634 | $ 24,534 | |
| Nyxol License Agreement [Member] | |||
| Liquidity [Abstract] | |||
| Non-refundable upfront payment received | $ 35,000 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of non-refundable upfront payment received under the license and collaboration agreement with FamyGen Life Sciences, Inc. No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|